Skip to main content

Table 1 Patient characteristics and baseline sHER2 levels

From: Monitoring serum HER2 levels in breast cancer patients

   N sHer2 values p values a
  Patients (N) 118 5.750 +/− 3.495  
Race Asian 7 9.11 0.041
Caucasian 81 5.23
African American 30 6.36
Age at diagnosis(years) mean ± sd   54.10 +/−13.81 0.813
≤45 32 5.38
>45 86 5.89
Tumor size (cm) mean ± sd   2.8- +/− 2.33 .852
T1 <2 53 5.49
T2 2-5 53 5.81
T3 >5 11 6.27
  N/A 1   
(+) axilla lymph node(s) 0 63 5.47 1.000
≥1 55 6.07
Receptor subtype tHer2+ 23 8.18 .032
tHer2-, ER/PR+ 77 5.02
TNBC 18 5.79
Clinical Outcome Disease Present 12 8.50 0.007
Disease Absent 106 5.44
Length of Follow Up (Months) Mean ± sd 23.51 +/− 11.38   
Median 21.32   
  1. Abbreviations: ER estrogen receptor, PR progesterone receptor, sHER2, soluble human epidermal growth factor receptor 2. aThis P value was determined using the Fisher’s test. N/A: in 1 patient, relevant information (e.g., tumor size) was missing